

ANNUAL REPORT

2022



**Saving lives of children with cancer
through excellence in medical care,
research and education.**

Table of Contents

About VIVA	01
Objectives	02
Message from the Chairman	03
Tribute to Dr Lee Seng Tee	04
VIVA-NUS Childhood Cancer Programme	05
VIVA-University Children Cancer's Centre (VUC3)	
VIVA-NUH Centre of Translational Research in Acute Leukemia (CentRAL)	
VIVA-Goh Foundation Professorship in Paediatric Oncology	06
VIVA-Goh Paediatric Oncology Fund	
Mrs Lee Kong Chian Chair in Advanced Cellular Therapy	07
VIVA-KKH Paediatric Brain and Solid Tumour Programme	08
VIVA Education Programme	09
Mrs Lee Kong Chian Chair in Advanced Cellular Therapy	07
VIVA-KKH Paediatric Brain and Solid Tumour Programme	08
VIVA Education Programme	09
VIVA Life Programme	19
VIVA Events	24
Chung Hwa Medical Institution @ VIVA	27
Finance Matters	28
Code of Governance	38
Board of Directors	40
External Advisory Board	41

About VIVA

The VIVA Foundation for Children with Cancer was incorporated in Singapore on 6 February 2006 as a Public Company Limited by Guarantee. It was registered under the Charities Act on 25 April 2006, with Institution of Public Character (IPC) status.

UEN:	200601578E
Charity Registration No.:	01961
IPC Effective Period:	15 May 2021 – 14 May 2024
HEF Registration Number:	HEF 0105/G
Registered Address:	8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470
Chairman:	Mrs Jennifer Yeo (Mdm Leong Lai Peng)
Auditors:	Assurance Partners LLP
Bankers:	Citibank Singapore Ltd DBS Bank Ltd Oversea-Chinese Banking Corporation Ltd United Overseas Bank Ltd



Objectives

To improve the cure rate of children with cancer and to help survivors thrive, so that they can live long, healthy, happy and meaningful lives through:



RESEARCH

Partnering and funding scientists and doctors in key projects and clinical research.



MEDICAL CARE

Providing the best facilities and the best level of care.



LIFE PROGRAMME

Supporting children with cancer and survivors in getting back on their feet and contributing back to society as healthy and equipped individuals.



EDUCATION

Empowering doctors, nurses and care-providers through training and knowledge sharing.

Message from the Chairman

Gratitude Beyond Measure:
A heartfelt appreciation to our donors,
volunteers and supporters.
Your remarkable contributions have
transformed the lives of children with
cancer and their families.
Together, We've Made Miracles Possible.



Dear friends,

For the year 2022, we at VIVA, would like to express our heartfelt gratitude for your unwavering support throughout the year. Your kindness and generosity have indeed made a tremendous difference in the lives of children with cancer and their families. This has been a challenging year, but it is filled with miracles. We are proud of our progress in providing support and care to those who need it most.

We organised more than 27 in-person events with over 1000 registrations for our Life Programme for survivors, which included tuition, art therapy sessions and swimming lessons. We also launched the survivorship programme for healthcare professionals, the first of its kind in the world with Series One comprising 12 virtual webinars and 25 international faculty to help them gain a better understanding of the long-term effects of cancer treatment affecting childhood cancer survivors who are at greater risk of future cancers and diseases. The Series One webinars attracted almost 4700 registrations from 61 countries. Series Two of the virtual webinars will continue to be held into 2023. Overall in 2022, we hosted 46 virtual webinars for medical professionals to educate them in different areas of pediatric oncology. These virtual webinars garnered over 16,000 registrations from 61 countries across the globe.

We are thankful to everyone who has supported us this year, from Tanya Sen and friends who presented a heartwarming concert in aid of VIVA, graced by President, Mdm Halimah Yacob, to Edmund Tie and the organising committee of the concert for presenting a fundraising concert, 'An Evening of Pop Opera with Fivera' held at Singapore Botanic Gardens, graced by Health Minister, Mr Ong Ye Kung, who helped us to raise awareness of childhood cancer at the concert. We would also like to thank violin child prodigy, Isabel Tan, for presenting a memorable concert in aid of VIVA, at which I was invited to play a Mozart Concerto with her orchestra.

Once again, to all our donors, volunteers, and supporters, we thank you from the bottom of our hearts. Your contributions have improved the lives of children with cancer and their families significantly. We could not have achieved what we did without your generous contributions.

With gratitude and warm wishes,

Mrs Jennifer Yeo

Executive Chairman (Pro bono) and Founder
VIVA Foundation for Children with Cancer

IN LOVING MEMORY OF DR LEE SENG TEE:

A VISIONARY SUPPORTER OF MRS LEE KONG CHIAN CHAIR IN ADVANCED CELLULAR THERAPY



In memoriam,
we honor
Dr Lee Seng Tee
for his contributions
to cancer research
and treatment. We
would also like to
express our deepest
condolences to his
loved ones.
May his legacy of
compassion and
dedication to the
betterment of
society live on.

It is with deep sorrow and heartfelt gratitude that we remember Dr Lee Seng Tee, a visionary philanthropist, and the driving force behind the Lee Foundation. Dr Lee Seng Tee's unwavering support has played a pivotal role in the establishment and success of the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy, an initiative by VIVA Foundation for Children with Cancer.

Thanks to the generosity of Dr Lee Seng Tee and the Lee Foundation, Mrs Lee Kong Chian Chair in Advanced Cellular Therapy by VIVA Foundation is able to support renowned experts such as Professor Dario Campana and his team at the National University of Singapore to conduct research on cell-based therapy and clinical trials for breakthroughs in cancer treatment. Among these remarkable advancements is the development of experimental CAR-T cellular immunotherapy, developed by Chair Prof Campana. His work in utilizing immune cells for cancer treatment earned him the prestigious 2020 Singapore President's Technology Award, underscoring the impact of his contributions to the field. The clinical results work in using CAR-T cells in the treatment of both children and adults are highly encouraging. These results hold the promise of ushering in a new era for ALL treatment.

VIVA Foundation is grateful for the ongoing collaboration since the Chair's inception in 2013. We extend our sincere appreciation to Dr Lee Seng Tee and the Lee Foundation for their unwavering commitment to advancing cancer research and treatment. Their profound impact will be felt for generations to come. Though Dr Lee Seng Tee may have passed on, his spirit and his commitment to making a difference will continue to guide us. His legacy will forever be cherished, and his philanthropic endeavors will continue to inspire us in our relentless pursuit of finding innovative solutions to combat childhood cancer.

VIVA-NUS CHILDHOOD CANCER PROGRAMME

VIVA-UNIVERSITY CHILDREN CANCER'S CENTRE (VUC3)



The VIVA-University Children's Cancer Centre (VUC3) is VIVA's first childhood cancer centre of excellence. The VUC3 provides a comprehensive childhood cancer treatment programme with capabilities of advanced cellular therapies and the right setting of care with a 16-bed Day Therapy Centre for chemotherapy. It is housed at the National University Hospital (NUH).

Medical Care (2022)

388 Inpatient Visits

6522 Outpatient Visits

6 CAR-T Cell Therapy

3 Bone Marrow Transplant

In the year 2022, the VUC3 continued its mission to provide excellent medical care for children with cancer, with 92 patients; 35 of those were Singapore resident patients and 57 were non-resident patients. With the borders reopening in 2022, the VUC3 also observed an increase in both inpatient and outpatient visits - a total of 388 inpatient visits and 6522 outpatient visits. Specialists at the VUC3 also conducted 6 CAR-T infusions and 3 Bone Marrow Transplants over the course of 2022.

The VUC3 also contributed to the fight against COVID-19 by vaccinating high-risk children, resulting in a surge of 669 cases registered in 2022 (199 cases in 2021).

To date, the team at VUC3 has taken part in 8 local collaborative clinical studies/ trials and 7 regional collaborative clinical studies/ trials.

VIVA-NUH CENTRE OF TRANSLATIONAL RESEARCH IN ACUTE LEUKEMIA (CENTRAL)



In 2014, VIVA set up the VIVA-NUS Centre for Translational Research in Acute Leukaemia (CentRAL) in collaboration with the National University of Singapore. CentRAL's key objective was to improve the cure rate and quality of life of patients with leukaemia and haematologic cancer in Singapore and Asia, through accurate leukaemia classification, prediction and determination of treatment response.

In December 2020, VIVA donated \$1.3M to provide support for 10 CAR-T cell products for children and young adults, as well as support costs, related to CAR-T therapy for needy families. Since 2022, CentRAL has completed the delivery of 7 CAR-T products to 7 patients (6 children, 1 young adult). Of the 7 patients, 4 received cell infusions in 2022. Out of the 7, 2 have unfortunately passed away.

VIVA-GOH FOUNDATION PROFESSORSHIP IN PAEDIATRIC ONCOLOGY



In 2012, Associate Professor Allen Yeoh was appointed the VIVA-Goh Foundation Associate Professor in Paediatric Oncology at the National University of Singapore. The Professorship was created to advance childhood cancer care in Singapore and across Asia.

In 2022, A/Prof Yeoh received the Long Service Medal at the National Day Awards on 9 August 2022. Following that, A/Prof Allen received the Team Award for CAR-T at the NUHS Tribute Awards Ceremony on 12 August 2022, which celebrates outstanding healthcare professionals and administrators. He has also published five papers in PREMIER journals in 2022, which ranked among the top 10% of publications by the Ministry of Health.

- ✓ On 4 May 2022, A/Prof Yeoh was featured on a Channel NewsAsia (CNA) Documentary Series: Innovating for The Future. In collaboration with CNA, NUS developed this documentary series. The series looked at how the diverse talent in the university community is catalyzing positive change in Singapore and beyond.
- ✓ On 14 October 2022, he appeared in a media release which featured The Khoo Teck Puat - National University of Children's Medical Institute (KTPNUCMI) at the National University Hospital (NUH) that celebrates 60 years of advancing child health. The event was graced by Singapore's Minister of Health, Mr Ong Ye Kung.
- ✓ A/Prof Yeoh was also featured in the 60 Years of Child Health Video Series: Our History, Present & Future.

VIVA-GOH PAEDIATRIC ONCOLOGY FUND

The VIVA-Goh \$12M grant was initially conceived to fund the VIVA-Goh Children's Cancer Programme. The aim of the programme was to achieve excellence in the treatment of cancer through (1) translational and clinical research and (2) training and education of doctors and nurses.

As reported from 2009 to 2014, the programme has achieved the major original targets for the St. Jude VIVA Childhood Leukemia Programme. Over the next 8 years, the remaining funds were used to support niche areas such as the manpower of resident physicians, clinical study coordinators, nurse lecturer, research staff and laboratory staff. By the end of 2022, funds have been fully used.



Sister Laura Tan Mei Lin
Senior Nurse Educator in VIVA
University Children's Cancer Centre
VIVA Volunteer Nurse

Sister Laura Tan Mei Lin; St. Jude-VIVA Global Senior Nurse Lecturer, who is supported by the VIVA-Goh grant runs the St. Jude-VIVA Asia Pacific Institute Nursing. She has also taken up the role of Patient Navigator, co-funds by Love, Nils Foundation.

In 2022, Sister Laura organised the 16th St. Jude-VIVA Forum 2022 - VIVA-Asia Nursing Symposium and the VIVA-Self-Care Webinars Programme.

MRS LEE KONG CHIAN CHAIR IN ADVANCED CELLULAR THERAPY

A Tribute to Excellence:
Celebrating
Prof Dario Campana's
Remarkable Accolades



GABBAY AWARD IN BIOTECHNOLOGY AND MEDICINE 2019
SINGAPORE PRESIDENT TECHNOLOGY AWARD 2020
FARNESINA AWARD 2023

VIVA began the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy with the support of the Lee Foundation, which supports renowned experts Dario Campana and his team at the National University of Singapore to conduct research on cell-based therapy and clinical trials for breakthroughs in cancer treatment.

One such treatment is the experimental CAR-T cellular immunotherapy which was developed by the Chair Professor Campana, who won the 2020 President's Technology Award for his work in using immune cells for the treatment for cancer.

The clinical results in using CAR-T cells in the treatment of both children and adults are highly encouraging. These results promise to usher in a new era in ALL treatment.

The work done under Mrs Lee Kong Chian Chair has also since unlocked over \$6M of additional research funding from NCIS Cancer Centre, the Goh Foundation, the Lee Foundation, and the Children's Cancer Foundation, amongst others. To this end, Dr Campana recently obtained his 3rd consecutive Singapore Translational Research (STaR) Investigator Award offered by the Ministry of Health's National Medical Research Council to support his research. This additional funding ensures that we can all continue the development of new cures that can save the lives of children with cancer.

VIVA is grateful for this ongoing collaboration since the Chair's inception in 2013 and we would also like to thank all our donors for their contributions to this programme.

VIVA-KKH PAEDIATRIC BRAIN AND SOLID TUMOUR PROGRAMME



Seated (L to R): Dr Mary Nheb, Dr Chen Wanwan, Dr Huma Faiz Halepota. Standing (L to R): Dr Yusran Othman, Associate Professor Kenneth Chang, Member, Steering Committee, VIVA-KKH PBST Programme, and Head and Senior Consultant, Department of Pathology and Laboratory Medicine, KKH, Dr Amos Loh, Chairman, Steering Committee, VIVA-KKH PBST Programme, and Senior Consultant, Department of Paediatric Surgery, KKH.

Credit to KK Women's and Children's Hospital

The VIVA-KKH Paediatric Brain and Solid Tumour Programme was established in 2015. The programme is a collaborative clinical and research partnership between VIVA, KK Women's and Children's Hospital (KKH), and St. Jude Children's Research Hospital to seek advancements in childhood brain and solid tumours by improving clinical care, translational research, education and leveraging the expertise and strength of partner institutions.

By 2022, the net research output of the Programme has amounted to 104 publications in peer-reviewed journals and 102 presentations. The Principal Investigators (PIs) supported by the Programme have earned 27 competitive grants totaling \$4.8 million to supplement the funding from the Programme.

The total number of clinical fellows/ observers trained under the fellowship programme at the end of 2022 is 8, including 5 observerships in paediatric pathology and 3 fellowships in paediatric surgical oncology.

In total, the Programme has developed and launched 6 key new lab-developed tests, specially catered for paediatric brain and solid tumours since its establishment. The brain tumours multi-disciplinary team clinic continues to improve care for patients with brain tumours, as patients could save time and benefit from the combined consultation at the one-stop outpatient clinic. An increasing number of patients have sought consultations at the molecular tumour board.

Medical Care and Achievements

\$4.8 million	Grants
104	Publications
102	Presentations

Multidisciplinary Tumour Boards (2022)

58 patients	Molecular Tumour Board
49 patients	Brain Tumour Board
206 patients	Solid Tumour Board



(From left) Dr Mary Nheb and Dr Chen Wanwan, with Prof Kenneth Chang in the pathology laboratory.


Credit to KK Women's and Children's Hospital

VIVA Education Programme

Virtual Empowerment Unleashed.

Celebrating VIVA's webinar journey.

Embracing the virtual era. Empowering healthcare professionals and nurturing self-care and wellness education



**IMPACT
SNAPSHOT**

46 Webinar sessions

61 Countries

16409 Registrations

ST. JUDE-VIVA SURVIVORSHIP

● CHILDHOOD CANCER SURVIVORSHIP CARE WEBINAR SERIES ●

The VIVA Foundation for Children with Cancer partnered with St. Jude Children's Research Hospital to produce the first-of-its-kind webinar series focusing on children's cancer survivorship care. The goal is to educate healthcare providers on the medical and psychological risks associated with childhood cancer and its therapy.

The first webinar series began twice monthly in January and ran for six months. The series addressed a wide range of crucial survivorship topics including 'Introduction to late effects and survivorship care planning,' 'Organ health after childhood cancer,' 'Reproductive late effects and pregnancy outcomes,' and others.

The series returned for six more sessions between October 2022 and 5 March 2023. The format of the second series shifted from lectures to case presentations and discussions. The series concentrated on the application of survivorship methods and therapies in high, middle and low-income countries.



Organising Chair

Dr Melissa Hudson

Director, Cancer Survivorship Division
Co-Leader, Cancer Control & Survivorship
Programme
The Charles E. Williams Endowed Chair of
Oncology-Cancer Survivorship



St. Jude–VIVA Survivorship

Series 1 in numbers

4,708
registrants



From more than
61
Countries

24
Faculty

12
Sessions

Series 2 in numbers

2,279
registrants



From more than
49
Countries

3
Faculty

3
Sessions, 3
more in 2023

16TH ST. JUDE-VIVA FORUM

Paediatric Oncology • VIRTUAL CONFERENCE 2022



Every year, VIVA Foundation for Children with Cancer organises the annual St. Jude-VIVA Forum (SJVF) in partnership with the St. Jude Children's Research Hospital in Memphis, Tennessee, the National University Healthcare System (NUHS), and the KK Women's and Children's Hospital (KKH).

Due to Covid-19 measures, we organised the 16th St. Jude-VIVA Forum 2022 online. The 16th St. Jude-VIVA Forum 2022 took place from 5 March 2022 to 7 & 8 April 2022. With a total of 58 faculty members, the forum was a resounding success, garnering over 6,700 registrants from more than 61 countries.

6,700
registrants

From more than
61
Countries



58
Faculty

14
Sessions

Strategic Partners of VIVA Singapore and VIVA China and the 25 hospitals that are part of the CCCG-ALL study group supported by VIVA China

1. National University of Singapore (Singapore)
2. KK Women's and Children's Hospital (Singapore)
3. St Jude Children's Research Hospital (Memphis, USA)
4. Shanghai Children's Medical Center (Shanghai, PRC)
5. Shanghai Soong Ching Ling Foundation (Shanghai, PRC)
6. Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center (Shanghai, PRC)
7. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Tianjin, PRC)
8. Hong Kong Children's Hospital, The Chinese University of Hong Kong (Hong Kong)
9. Chongqing Medical University Affiliated Children's Hospital (Chongqing, PRC)
10. Children's Hospital of Soochow University (Soochow, PRC)
11. Anhui Medical University Second Affiliated Hospital (Anhui, PRC)
12. Children's Hospital of Nanjing Medical University (Nanjing, PRC)
13. West China Second University Hospital, Sichuan University (Sichuan, PRC)
14. Nanfang Hospital, Southern Medical University (Guangdong, PRC)
15. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, PRC)
16. The Affiliated Hospital of Qingdao University (Qingdao, PRC)
17. Children's Hospital Affiliated to Shanghai Jiaotong University (Shanghai, PRC)
18. Children's Hospital of Fudan University (Shanghai, PRC)
19. Qilu Hospital of Shandong University (Shandong, PRC)
20. Xi 'an Northwest Women's and Children's Hospital (Xi'an, PRC)
21. Union Hospital of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, PRC)
22. Jiangxi Provincial Children's Hospital (Nanchang, PRC)
23. Xiangya Hospital Central South University (Hunan, PRC)
24. Guangzhou Women and Children's Medical Center (Guangzhou, PRC)
25. Fujian Medical University Union Hospital (Fujian, PRC)
26. Anhui Provincial Cancer Hospital (Anhui, PRC)
27. The People's Hospital of Guangxi Zhuang Autonomous region (Guangxi, PRC)
28. The Affiliated Hospital of Guizhou Medical University (Guizhou, PRC)
29. Hunan Children's Hospital (Hunan, PRC)
30. Shenzhen Children's Hospital (Shenzhen, PRC)

Gut Microbiome and Cancer



Organising Chair
Prof Joseph Sung

Distinguished University Professor
Senior Vice President (Health & Life Sciences)
Dean, Lee Kong Chian School of Medicine
Nanyang Technological University,
Singapore

VIVA Foundation organised the VIVA Gut Microbiome and Cancer Webinar Series from July to December 2022, in conjunction with Prof Joseph Sung, Dean of Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. The series' goal was to educate medical professionals on the significance of the gut microbiota in cancer.

2,523
registrants

From



43
Countries

Special thanks to Dr Sunny Wong, Prof Alfred Cheng and Dr Joanne Ngeow for contributing to success of the webinar series.




Convenors



Prof Godfrey Chan

Chief of Service, Department of Paediatrics, HKU-Shenzhen Hospital
Tsao Yen-Chow Endowed Professor in Paediatrics,
HKU Honorary Consultant, Department of Paediatrics,
Hong Kong Children's Hospital



Dr Anthony Liu

Clinical Assistant Professor
Department of Paediatrics & Adolescent Medicine
Hong Kong Children's Hospital
LKS Faculty of Medicine, The University of Hong Kong

VIVA-Asia Rare Tumour Board is a virtual quarterly online meeting that is organised by VIVA Foundation for Children with Cancer. The aim of the meeting is to enable doctors from all over the world to discuss the diagnosis and treatment of rare pediatric tumours.

In 2022, the meeting continued onto its 9th and 10th sessions.



We thank all the speakers and panelists who have contributed over the past 3 years.



VIVA-ASIA BLOOD AND MARROW TRANSPLANT SCHOOL



Since 2017, the VABMT Consortium has organised a series of 'VABMT Schools' with the mission of bringing together international and regional experts to educate physicians on the latest advances and best practices in paediatric HSCT.



The Spring School 2022 took place on the 16th St. Jude-VIVA Forum, organised by Dr Rajat Bhattacharyya and Dr Michaela Seng of KK Women's and Children's Hospital, Singapore.



The Autumn School held in October 2022 was organized by the Hong Kong team, spearheaded by Prof Godfrey Chan and Dr Pamela Lee of Hong Kong Children's Hospital, Hong Kong.



VIVA Self-Care Programme Webinar seeks to impart self-care skills and knowledge such as communication, mindfulness, diet, and nutrition to patients, caregivers, healthcare professionals, and the public.



In 2022, the Self-Care Programme returned with a two-part webinar series entitled 'Effective Communication in Illness Journey.' In this series, we looked at improving communication among healthcare professionals, parents, survivors and their caregivers.





Post Forum VIVA-Asia Nursing Symposium



The Post Forum VIVA-Asia Nursing Symposium was held on 7 May 2022. The session was moderated by Prof Quah with Dr James Huang from NUH who spoke about Pre/Probiotic: Friend or Foe?

患教线上直播

患者和护理者教育线上研讨会

急性淋巴细胞白血病的 嵌合抗原受体T细胞疗法的实际考虑



CAR T-Patient Education Webinar

VIVA conducted a two-part Mandarin CAR-T webinar for patients, survivors and their caregivers. The sessions were moderated by Prof Wing Leung from The University of Hong Kong (HKU).



VIVA Life Programme

Empowering Lives



VIVA Life Programme is developed to help survivors in self-care and provide hope and skills through conducting programmes and activities to enhance and maintain their physical, as well as, mental health and wellness.

Snappy Stats



Easter Day Party



An Easter Party was held at VIVA Hub on Saturday, 23 April 2022. The party was organised by volunteers from By the Grace of God JTL Grant Making Project. VIVA welcomed over 50 beneficiaries and their families to this party where they took part in activities which included a storytelling session through art, jewellery-making, egg decoration and treasure hunt.

Drone workshop



The very first Drone workshop was conducted at VIVA Hub by volunteer, Hong Yanci and 5 VIVA volunteers on 4 June 2022, Saturday. VIVA had a total of 50 participants which included VIVA's beneficiaries and their families.

Wolfgang Little Maestro' orchestra



The Wolfgang Young Artistes Orchestra conducted 10 sessions starting on 4 June 2022 at VIVA Hub.

Fridge Magnet Painting Workshop



The Fridge Magnet Painting Workshop took place on 10 June 2022 at VIVA Hub. The beneficiaries attended a hands-on session where they painted and took home their painted ceramic fridge magnets.

Art Connection Workshop #1



The first Art Workshop led by volunteers from By the Grace of God JTL Grant Making Project was held on 18 June 2022 at VIVA Hub. The beneficiaries had a chance to express their creativity by designing colourful face masks.



In partnership with The Movement Studio, VIVA's first dance activity workshop - 'Core and Coordination Workshop' was held at VIVA Hub on 30 July 2022. This workshop aimed to build self-confidence and nurture a positive mindset through movement and music.

The Wolfgang Young Artistes Orchestra featured one of VIVA's beneficiaries, Jay, who held a mini performance at VIVA Hub on 6 August 2022.



With a kind donation from Andre, VIVA distributed food items to the VIVA beneficiaries. Oat milk, canned mackerels and fresh vegetables were delivered on 24 and 25 September 2022.

The second Art Workshop led by volunteers from By the Grace of God JTL Grant Making Project was held on 15 October 2022 at VIVA Hub. The workshop fostered parent-child bonding through canvas painting activities.



VIVA was invited to join the "Polo Generation 2022" organised by Colts Polo on 13 November 2022, Sunday. The beneficiaries were given the opportunity to interact with the horses, try out polo and watch a live match.

VIVA Swimming Programme



In collaboration with The Schooling Effect, the “VIVA Swimming Programme” commenced on Saturday, 12 November 2022 at the Sport Schooling Centre. The programme aimed to provide an opportunity for the beneficiaries to learn to swim at their own pace and comfort level.

Circus: The Great Cirque des Cascades



Thanks to a kind donation from Mr Derek Cheung, VIVA's beneficiaries were invited to watch 'The Great Cirque des Cascades' at Bayfront Event Space, Marina Bay. The spectators were immersed in the spectacular sights as they witnessed near-impossible routines and jaw-dropping performances.

A Day with the Navy



“A Day with the Navy” was held on 30 November 2022, Wednesday. The event was organised in collaboration with The Republic of Singapore Navy at RSS Singapura. This event gave the VIVA community an opportunity to have an educational day with the Navy.

Trees of the World



VIVA was invited to participate in 'Trees of the World' organised by Singapore Botanic Gardens. VIVA and its beneficiaries came together to create recyclable and sustainable decorations with help from Far East Organisation.

VIVA's beneficiaries were invited to watch The Nutcracker by the Singapore Ballet Company on 9 December 2022 at The Esplanade Theatre.



A VIVA Christmas Party was held on 10 Dec 2022 at VIVA Hub for VIVA's families, volunteers, tutors and supporters. We would like to thank Maria Fernandez and Cosentino, for raising \$5,200 together and sponsoring wonderful presents for the children and their families.

As we hope to spread love and joy during the Christmas season, VIVA gifted Christmas presents to KKH, NUH and Ain Society.



Thanks to our special volunteers - Jonathan Leong, John Lee, and Corey Koh, VIVA was able to spread Christmas joy to the children in the KKH wards.

Special thanks to Mr. Stephanus and Apollo Entertainment for donating tickets to VIVA's beneficiaries to watch the Magic Ice performance on 23 December 2022 at the Bayfront Event Space. They were treated to a 2,400 square meters winter playground and also live Christmas performances.



VIVA Events



Uniting Hearts and Harmony in Giving: Amplifying Support through Engaging Fundraising Events and Enchanting Musical Showcases, including the VIVA Fiesta Concert - A Vibrant Highlight of VIVA's 2022 Journey.

Tanya Sen & Friends Concert



In collaboration with Tanya Sen & Friends, VIVA was invited to attend the Tanya Sen Concert on 24 February 2022 at The Esplanade Theatre. VIVA's beneficiaries and guests were treated to an evening of songs and wonderful music. Singapore's President, Madam Halimah Yacob was the Guest of Honour at the fundraising concert. Thanks to our gracious donors and supporters, VIVA raised a total of \$172,4000, with a matching grant from Tote Board.

VIVA would like to pay tribute to the precious soul of Aiden Jerome De Silva, who left us on 3 March 2022.

Aiden's spirit shone brightly throughout his battle, reminding us of the true essence of bravery and determination. Despite the challenges he faced, he displayed an unwavering spirit that touched the hearts of everyone who had the privilege of knowing him.



Aiden and his parents at Tanya Sen Concert.



Rest in peace, dear Aiden. Your memory will forever be cherished and your undaunting spirit will inspire us as we strive to make a difference in the lives of children battling cancer.

AIA Donation



AIA raised funds for VIVA Foundation during their Tokidoki Run held at the end of 2021. A cheque of \$49,641 was presented to VIVA Foundation on 6 April 2022 by AIA CEO, Ms Wong Sze Keet. VIVA Director, Ms Shu Khoo and AIA CCDO, Ms Melita Teo were also present at the ceremony.

Musical Moments Isabelle & Friends



On 10 November 2022, a concert entitled 'Musical Moments - Isabelle & Friends' was held at The Esplanade Recital Studio. The audience was treated to elegant classical music performed by Isabelle, the Wolfgang Violin Studios, Ziline of Vocaline, Mrs Jennifer Yeo and EJ Loke. The concert raised over \$24,000. Special thanks to Mr and Mrs Tan Boon Khai, Mrs Annie Lee and our volunteers, Mr Lester Kong and his wife, Ziline Chen, for organising this concert.



Performed by the first and only Thai pop-opera group FIVERA, a charity concert was held at the Shaw Foundation Symphony Stage at the Singapore Botanic Gardens. The quintet of classically-trained musicians delighted and charmed the audience with their repertoire of classic operatic arias, as well as their renditions of international pop favourites.

The charity concert was graced by Singapore's Minister of Health, Mr Ong Ye Kung, who was the Guest of Honour at the fundraising event. About 5000 people were there at Singapore Botanic Gardens to enjoy the performance. The fundraising event raised close to \$1.4m. Special thanks to Mr Edmund Tie and the organising committee for presenting this fundraising concert.

Welcome to VIVA Hub

Chung Hwa Medical Institution @ VIVA



VIVA Foundation for Children with Cancer (VIVA) is pleased to announce the new development of our Survivor Life Programme which is aimed to support the health and well-being of children with cancer. The programme is in line with VIVA's core mission of helping children with cancer lead happier, healthier, and more productive lives by providing them with the necessary skills and support to take care of themselves.

As part of the Survivor Life Programme, VIVA has partnered with Chung Hwa Medical Institution to provide a Traditional Chinese Medicine (TCM) clinic at VIVA Hub for children with cancer. The TCM clinic was launched on 10 October 2022. It provides acupuncture and complementary Chinese medicine treatment to cancer survivors in the hope of strengthening their immune system, alleviating the toxic side effects of radiation and chemotherapy and reducing the risk of tumour recurrence and metastasis. VIVA aims to enable survivors to have access to alternative treatment methods to maintain good health and empower them to take charge of their own health.

In addition to medical services, VIVA and Chung Hwa Medical Institution will also provide continuing education and health education to healthcare professionals, the public and patients to help them understand complementary Chinese medicine treatment.

VIVA Foundation for Children with Cancer remains committed to improving the quality of life for children with cancer, and this partnership with Chung Hwa is an excellent example of how traditional Chinese medicine and Western medicine can work together to achieve this goal. We celebrate this exciting new development in our Survivor Life Programme which could support our efforts to provide the best possible care and support for children and families affected by cancer.

Statement of Financial Activities

For the Financial Year Ended 31 December 2022

	Note	Unrestricted funds S\$	Restricted funds S\$	2022 S\$	2021 S\$
Income					
Income from generated funds					
Voluntary income	(4a)	1,145,418	-	1,145,418	717,573
Investment income	(4a)	20,825	-	20,825	23,444
Activities for generating funds	(4a)	1,603,391	-	1,603,391	1,099,137
Endowment fund	(4a)	-	2,665,227	2,665,227	-
Income from charitable activities	(4b)	57,908	-	57,908	86,352
Other income	(4c)	4,945	-	4,945	46,678
Total income		2,832,487	2,665,227	5,497,714	1,973,184
Expenditures					
Cost of generating funds					
Cost of generating voluntary income	(5a)	9,986	-	9,986	17
Cost of activities for generating funds	(5a)	136,515	-	136,515	19,997
Cost of endowment fund	(5a)	11,098	-	11,098	-
Cost of charitable activities	(5b)	69,580	-	69,580	215,778
Governance costs	(5c)	1,157,363	-	1,157,363	1,108,297
Total expenditures		1,384,542	-	1,384,542	1,344,089
Net income before income tax expense		1,447,945	2,665,227	4,113,172	629,095
Income tax expense	(6)	-	-	-	-
Net movement in funds		1,447,945	2,665,227	4,113,172	629,095
Reconciliation of funds					
Total funds brought forward	(15)	25,990,267	-	25,990,267	25,361,172
Total funds carried forward		27,438,212	2,665,227	30,103,439	25,990,267

Excerpted from the full Audited Financial Report 1 Jan 2022 to 31 Dec 2022, which will be attached separately to this Annual Report.

Statement of Financial Position

For the Financial Year Ended 31 December 2022

	Note	2022 S\$	2021 S\$
Non-current assets			
Property, plant and equipment	(8)	<u>18,468,801</u>	<u>18,972,029</u>
Current assets			
Inventories	(9)	2,414	2,414
Other receivables	(10)	395,565	417,566
Cash and short-term deposits	(11)	<u>11,297,825</u>	<u>6,683,989</u>
		<u>11,695,804</u>	<u>7,103,969</u>
Current liabilities			
Accrued expenses	(12)	11,327	13,188
Deposit received	(13)	15,843	15,843
Other payables	(14)	<u>33,996</u>	<u>56,700</u>
		<u>61,166</u>	<u>85,731</u>
Net current assets		<u>11,634,638</u>	<u>7,018,238</u>
Total assets less current liabilities		<u>30,103,439</u>	<u>25,990,267</u>
Funds of Charity			
Unrestricted funds			
- General fund	(15)	<u>27,438,212</u>	<u>25,990,267</u>
Total unrestricted funds		<u>27,438,212</u>	<u>25,990,267</u>
Restricted funds			
- Endowment fund	(15)	<u>2,665,227</u>	<u>-</u>
Total restricted funds		<u>2,665,227</u>	<u>-</u>
Total Charity Funds		<u>30,103,439</u>	<u>25,990,267</u>

Statement of Cash Flow

For the Financial Year Ended 31 December 2022

	Note	2022 S\$	2021 S\$
<u>Cash flows from operating activities</u>			
Net income before income tax expense		4,113,172	629,095
<u>Adjustments for:</u>			
Depreciation of property, plant and equipment	(8)	506,466	524,096
Interest income		(20,825)	(23,444)
Operating cash flows before changes in working capital		<u>4,598,813</u>	<u>1,129,747</u>
<u>Changes in working capital:</u>			
Other receivables		22,001	(179,634)
Inventories		-	(150)
Accrued expenses		(1,861)	12,621
Deposit received		-	(34,171)
Other payables		(22,704)	8,175
Net cash flows generated from operating activities		<u>4,596,249</u>	<u>936,588</u>
<u>Cash flows from investing activities</u>			
Acquisition of property, plant and equipment	(8)	(3,238)	(48,693)
Increase in short-term deposits with maturity over 3 months		(20,818)	(22,750)
Interest received		20,825	23,444
Net cash flows used in investing activities		<u>(3,231)</u>	<u>(47,999)</u>
Net increase in cash and cash equivalents		4,593,018	888,589
Cash and cash equivalents at beginning of financial year		<u>3,161,239</u>	<u>2,272,650</u>
Cash and cash equivalents at end of financial year	(11)	<u><u>7,754,257</u></u>	<u><u>3,161,239</u></u>

Community Partnership

(Other Charity Funds)

The charity held donation drives to raise funds for specific projects. As of 31 December 2022, a total fund of S\$82,276,017 (2021:S\$82,276,017) was raised by the Charity with a government matching grant of S\$46,200,037 (2021: S\$46,200,037)

The details of the funds are divided into three categories as follows:

(A) Specific donations received under the Charity as donation income.

(B) Specific donations co-funded by the Charity and Community Partners; and

(C) Specific donations paid directly to the Community Partners as beneficiaries.

Except as disclosed in Note 14, the details of funds which are the donations and the amounts expended below are not reflected in the financial statements of the Charity.

	Cumulative Funds raised as at 31 December 2022		Fund balances raised as at 31 December 2022	
	Donation Received S\$	Government Matching Grant S\$	Donation Received S\$	Government Matching Grant S\$
(A) Specific donations received under the Charity as donation income				
Donated space (Note 15)	24,100,000	-	18,436,500	-
Available fund balance (Note 15)	14,603,987	-	9,001,712	-
VIVA-NUS CenTRAL (Note A1)	8,026,494	-	1,793	-
VIVA-Mr Goh Hup Jin Fund (Note A2)	1,300,174	-	1,071,077	-
Cancer Immunotherapy (Note A3)	1,003,612	-	-	-
	<u>49,034,267</u>	<u>-</u>	<u>28,511,082</u>	<u>-</u>
(B) Specific donations co-funded by the Charity and Community Partners				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note B1)	<u>13,257,349</u>	<u>12,951,588</u>	<u>3,344,973</u>	<u>12,950,000</u>
(C) Specific donations paid directly to the Community Partners as beneficiaries				
NUS Children Cancer Centre Fund (Note C1)	2,490,318	4,127,488	1,430,143	2,502,913
NUS Health Research Endowment Fund (Note C2)	3,590,296	3,227,040	-	5,549,105
VIVA Paediatric Oncology Fund (Note C3)	12,267,216	23,997,755	544,459	13,821,882
VIVA Education and Research Fund (Note C4)	672,374	1,300,620	-	768,593
	<u>16,698,104</u>	<u>32,452,903</u>	<u>1,974,602</u>	<u>22,642,493</u>
Total Funds	<u>78,989,720</u>	<u>45,404,491</u>	<u>33,830,657</u>	<u>35,592,493</u>

*For Notes, reference is made to Audit Report

Community Partnership

(Other Charity Funds)

	Cumulative Funds raised as at 31 December 2021		Fund balances raised as at 31 December 2021	
	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$
(A) Specific donations received under the Charity as donation income				
Donated space (Note 15)	24,100,000	-	18,918,500	-
Available fund balance (Note 15)	11,771,674	-	7,071,767	-
VIVA-NUS CenTRAL (Note A1)	8,026,494	-	1,793	-
VIVA-Mr Goh Hup Jin Fund (Note A2)	1,300,174	-	1,071,077	-
Cancer Immunotherapy (Note A3)	<u>1,003,612^(a)</u>	-	-	-
	<u>46,201,954</u>	-	<u>27,063,137</u>	-
(B) Specific donations co-funded by the Charity and Community Partners				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note B1)	<u>13,257,349</u>	<u>12,951,588</u>	<u>4,133,218</u>	<u>12,950,000</u>
(C) Specific donations paid directly to the Community Partners as beneficiaries				
NUS Children Cancer Centre Fund (Note C1)	2,490,318	4,127,488 ^(a)	1,430,143	2,502,913
NUS Health Research Endowment Fund (Note C2)	3,589,422 ^(a)	3,205,984	-	5,527,199
VIVA Paediatric Oncology Fund (Note C3)	12,267,216 ^(a)	23,997,755 ^(a)	544,459	13,821,882
VIVA Education and Research Fund (Note C4)	<u>672,374^(a)</u>	<u>1,300,620^(a)</u>	-	<u>768,593</u>
	<u>19,019,330</u>	<u>32,631,848</u>	<u>1,974,602</u>	<u>22,620,587</u>
Total Funds	<u>78,478,633</u>	<u>45,583,436</u>	<u>33,170,957</u>	<u>35,570,587</u>

These amounts have been revised and updated based on the Community Partner's most recent records.

*For Notes, reference is made to Audit Report

Community Partnership

(Other Charity Funds)

(A) Specific Donations Received under the Charity as Donation Income

The Charity received donations for certain designated funds. These donations were reflected in the financial statements of the Charity as donation income. Subsequently, the Charity donated these to the designated fund managed by the Community Partners. The donated amounts were reflected in the financial statements of the Charity as expenditures incurred for charitable activities. The details of the funds which the amounts expended are not reflected in the financial statements of the Charity are as follows:

(A1) VIVA-NUS Centre for Translational Research in Acute Leukaemia (“CenTRAL”)

	2022		2021	
	Donation Received S\$	Government Matching Grant S\$	Donation Received S\$	Government Matching Grant S\$
Balance at 1 January	1,793	-	1,793	-
<u>Add/(Less):</u>				
Donation received	-	-	-	-
Other income	-	-	-	-
Expenditure	-	-	-	-
Balance at 31 December	<u>1,793</u>	<u>-</u>	<u>1,793</u>	<u>-</u>
Total Funds Raised by the Charity	<u>8,026,692</u>	<u>-</u>	<u>8,026,692</u>	<u>-</u>

The funds were donated by the Charity to the National University of Singapore to support the advancement of education and research with the establishment of CenTRAL, a state-of-the-art leukaemia research and diagnostic facility with the key objective of improving the cure rate and quality of life of patients with leukaemia and haematologic cancer in Singapore and the Asia region, through accurate leukaemia classification, prediction and determination of treatment response.

(A2) VIVA-Mr Goh Hup Jin fund for Translational Research in Acute Leukaemia (“CenTRAL”)

	2022		2021	
	Donation Received S\$	Government Matching Grant S\$	Donation Received S\$	Government Matching Grant S\$
Balance at 1 January	1,071,077	-	1,300,000	-
<u>Add/(Less):</u>				
Donation received	-	-	-	-
Other income	-	-	174	-
Expenditure	-	-	(229,097)	-
Balance at 31 December	<u>1,071,077</u>	<u>-</u>	<u>1,071,077</u>	<u>-</u>
Total Funds Raised by the Charity	<u>1,300,000</u>	<u>-</u>	<u>1,300,000</u>	<u>-</u>

The funds were donated by Mr Goh Hup Jin to support the advancement of education and research at CenTRAL. As of 31 December 2020, these amounts have been subsequently donated by the Charity to CenTRAL.

Community Partnership

(Other Charity Funds)

(A3) Cancer Immunotherapy

	<u>2022</u>		<u>2021</u>	
	<u>Donation Received</u> S\$	<u>Government Matching Grant</u> S\$	<u>Donation Received</u> S\$	<u>Government Matching Grant</u> S\$
Balance at 1 January	-	-	-	-
<u>Add/(Less):</u>				
Donation received	-	-	-	-
Balance at 31 December	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total Funds Raised by the Charity	<u>1,003,612</u>	<u>-</u>	<u>1,003,612</u>	<u>-</u>

The funds were donated by the Charity to Yon Loo Lin School of Medicine, National University of Singapore, to fund cancer immunotherapy clinical research, specifically to support clinical trials of novel therapies based on immune cells for children and adults with drug-resistant cancer. In 2014, a S\$1 million donation was made to NUS by the charity.

(B) Specific Donations Co-funded by the Charity and Community Partners

The Charity and Community Partners raised funds separately where the contributions by donors were designated for specific purposes. The Charity donations were reflected in the financial statements of the Charity as Donation income. Subsequently, when the Charity donated these to the designated funds managed by the Community Partners, the amounts were reflected in the financial statements of the Charity as an expenditure incurred for charitable activities. The details of the funds in which the amounts expended were not reflected in the financial statements of the Charity are as follows.

(B1) VIVA-KKH Childhood Brain and Solid Cancers Programme

	<u>2022</u>		<u>2021</u>	
	<u>Donation Received</u> S\$	<u>Government Matching Grant</u> S\$	<u>Donation Received</u> S\$	<u>Government Matching Grant</u> S\$
Balance at 1 January	4,133,218	12,950,000	5,017,997	12,950,000
<u>Add/(Less):</u>				
Expenditures	<u>(788,245)</u>	<u>-</u>	<u>(884,779)</u>	<u>-</u>
Balance at 31 December	<u>3,344,973</u>	<u>12,950,000</u>	<u>4,133,218</u>	<u>12,950,000</u>
Total Funds Raised by the Charity	<u>13,257,349</u>	<u>12,951,588</u>	<u>13,257,349</u>	<u>12,951,588</u>

The funds were donated by the Charity to KKH Health Fund (Formerly known as KKH Health Endowment Fund) used for the advancement of the treatment and cure for children with brain and solid tumours in Singapore and the Asia Pacific region under the VIVA-KKH Childhood Brain and Solid Cancers Programme. This programme focuses on four areas of childhood brain and solid cancers in clinical care, translational research, registry-based population science, and collaborative education and training.

Community Partnership

(Other Charity Funds)

(C) Specific Donations Paid Directly to Community Partners as Beneficiaries

The Charity raised funds for the following four projects, where the contribution by donors was designated for specific purposes and paid directly to the Community Partners. The details of the funds which are the donations and the amount expended below are not reflected in the financial statements of the Charity as follows.

(C1) NUS Children Cancer Centre Fund (“CCCF”)

	<u>2022</u>		<u>2021</u>	
	Donation Received S\$	Government Matching Grant S\$	Donation Received S\$	Government Matching Grant S\$
Balance at 1 January	1,430,143	2,502,913	1,475,950	2,530,639
<u>Add/(Less):</u>				
Investment income	-	-	1,636	134,519
Other income	-	-	60	-
Expenditure	-	-	(47,503)	(159,939)
Investment loss	-	-	-	-
Transfer to unrestricted endowment fund	-	-	-	-
Transfer to unrestricted non-endowment fund	-	-	-	(2,306)
Balance at 31 December	<u>1,430,143</u>	<u>2,502,913</u>	<u>1,430,143</u>	<u>2,502,913</u>
Total Funds Raised by the Charity	<u>2,490,318</u>	<u>4,127,488</u>	<u>2,490,318</u>	<u>4,127,488</u>

The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as VIVA-University Children’s Cancer Centre (“VUC3”) at the National University Hospital which will be the centre of excellence for the treatment and cure of childhood cancer, particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by VIVA Foundation and by Singapore Totalisator Board.

Community Partnership

(Other Charity Funds)

(C2) NUS Health Research Endowment Fund (“HREF”)

	<u>2022</u>		<u>2021</u>	
	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$
Balance at 1 January	-	5,527,199	2,294,228	3,000,000
<u>Add/(Less):</u>				
Other income	-	21,930	27,011	5,984
Donation received	-	-	-	200,000
Expenditures	-	(24)	(6)	(18)
Transfer to unrestricted endowment fund	-	-	(2,321,233)	2,321,233
Balance at 31 December	<u>-</u>	<u>5,549,105</u>	<u>-</u>	<u>5,527,199</u>
Total Funds Raised by the Charity	<u>3,590,296</u>	<u>3,227,040</u>	<u>3,589,422</u>	<u>3,205,984</u>

The funds were donated to the National University Hospital to establish the Mrs. Lee Kong Chian Memorial chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the VIVA Children's Cancer Programme. The Donation of S\$3 million was received from the Lee Foundation, via the VIVA Foundation and was matched by the Ministry of Health with S\$3 million in two payments received on December 2006 and March 2007. The Money was used as a bridging loan to support the setting up of the VIVA University Children's Cancer Centre.

(C3) VIVA Paediatric Oncology Fund (“VPOF”)

	<u>2022</u>		<u>2021</u>	
	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$	Donation <u>Received</u> S\$	Government Matching <u>Grant</u> S\$
Balance at 1 January	544,459	13,821,882	1,343,039	13,719,635
<u>Add/(Less):</u>				
Investment income	-	-	-	752,750
Other income	-	-	259	-
Expenditure	-	-	(798,839)	(609,915)
Investment loss	-	-	-	-
Transfer to unrestricted endowment fund	-	-	-	(40,588)
Transfer to unrestricted non-endowment fund	-	-	-	-
Balance at 31 December	<u>544,459</u>	<u>13,821,882</u>	<u>544,459</u>	<u>13,821,882</u>
Total Funds Raised by the Charity	<u>12,267,216</u>	<u>23,997,755</u>	<u>12,267,216</u>	<u>23,997,755</u>

The VIVA Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with a matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund is used to advance paediatric oncology including, but not limited to, supporting the VIVA University Children's Cancer Centre and St. Jude VIVA Children's Cancer programme. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish strategic research programmes in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.

Community Partnership

(Other Charity Funds)

(C4) VIVA Education and Research Fund (“VERF”)

	<u>2022</u>		<u>2021</u>	
	<u>Donation</u>	<u>Government</u>	<u>Donation</u>	<u>Government</u>
	<u>Received</u>	<u>Matching</u>	<u>Received</u>	<u>Matching</u>
	<u>S\$</u>	<u>Grant</u>	<u>S\$</u>	<u>Grant</u>
	<u>S\$</u>	<u>S\$</u>	<u>S\$</u>	<u>S\$</u>
Balance at 1 January	-	768,593	-	776,215
<u>Add/(Less):</u>				
Investment income	-	-	-	40,206
Investment loss	-	-	-	-
Expenditure	-	-	-	(47,703)
Transfer to unrestricted non-endowment fund	-	-	-	(125)
Balance at 31 December	<u>-</u>	<u>768,593</u>	<u>-</u>	<u>768,593</u>
Total Funds Raised by the Charity	<u>672,374</u>	<u>1,300,620</u>	<u>672,374</u>	<u>1,300,620</u>

The funds were donated by the Charity to the National University of Singapore, Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the VIVA Children’s Cancer Programme and income and expenses for the Annual St. Jude VIVA Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Charity.

CODE OF GOVERNANCE

COMPLIANCE WITH THE CODE OF GOVERNANCE

VIVA Foundation constantly works towards compliance with the Charities Act, Charities (Institutions of Public Character) Regulations, Charities Accounting Standards, the Code of Governance for Charities and IPCs and the Personal Data Protection Act, and take steps to address and resolve weakness/es where appropriate.

MANAGING CONFLICT OF INTEREST

VIVA Foundation has in place a policy relating to the management and avoidance of conflict of interest. All Members, Directors and staff are required to sign the prescribed Declaration of Conflict of Interest form when they are appointed and thereafter annually or whenever there is any material change in the information contained in their respective Declarations.

ONLINE GOVERNANCE EVALUATION CHECKLIST (GEC) via CHARITY PORTAL

VIVA Foundation has been submitting the GEC annually via the Charity Portal. These are also available on VIVA's website at www.viva.sg.

RESERVES POLICY

VIVA Foundation has set aside a reserve of \$1.4 million to provide financial stability and resources for the development of its principal activities. The Board will periodically review the amount of reserves that are required to ensure adequacy in fulfilling the Foundation's obligations.

SALARIES AND RELATED COSTS

No Directors received any remuneration. During the financial year 2022, no staff personnel received an annual remuneration of \$100,000.00 and above. No staff is involved in setting his/her own remuneration.

VIVA discloses that there is no paid staff, being a close member of the family belonging to the Executive Head or a governing board member of the charity, who has received remuneration exceeding \$50,000 during the financial year.

VOLUNTEER MANAGEMENT

VIVA discloses that there are volunteer management processes in place for volunteers.

REELECTION OF DIRECTORS

Board of Directors appointed during the financial year was re-elected by the Members at the Annual General Meeting.

VIVA Foundation does not have term limits for Directors/Members as the Board believes that continued contribution by each Director provides benefits to the foundation. Each Director's integrity is not compromised by the long period of service.

The Board decided, with the Members' approval, that Directors who serve on the Board for more than 10 years are retained. All Directors who are over the age of 70 years were re-appointed to hold office until the conclusion of the next Annual General Meeting of the Company pursuant to Section 153(6) of the Companies Act, Chapter 50.

BOARD MEMBERS' ATTENDANCE AT MEETINGS

During the year, 4 Ordinary Board Meetings were held. A Director who is unable to attend any meeting in person may participate via teleconference.

The attendance of each member of the governance board at meetings is as follows:

S/No.	Name	Attendance
1	LEONG LAI PENG	4/4
2	KUOK OON KWONG	2/4
3	TAN BEE LAN	1/4
4	WILSON CHRISTOPHER GEOFFREY	2/4
5	TAN WEI CHONG, MARTINO	3/4
6	SHULAMITE N K KHOO	3/4
7	YEONG YOON YING	2/4
8	PHUA SIOK GEK CYNTHIA	3/4
9	LIN DIAAN YI	3/4
10	CHUA KHENG KOK	3/4
11	THAM SAI CHOY	3/4

The Board is satisfied that each Director is committed to fulfilling the mission of VIVA Foundation. This is evidenced by their respective valuable contributions in many ways despite not attending some or all of the meetings during the year due to prior commitments.

CODE OF GOVERNANCE

INTERNAL CONTROL AND RISK MANAGEMENT MEASURES

The Board assumes overall responsibility and is fully committed to maintaining a sound system of internal control and risk management that provide reasonable assurance of effective operations and statutory compliance in accordance with the Code of Governance and Charity Accounting Standards.

The Board ensures that there is a sound internal control policies and procedures in place.

The Board constantly reviews, taking into account changes in the regulatory and statutory, these policies and procedures to ensure adequacy and effectiveness.

The Board has also put in place a risk management policy. One of these policies is the implementation of internal controls as part of the day-to-day operations.

BOARD OF DIRECTORS

In 2022, four (4) Ordinary Board Meetings and one (1) Annual General Meeting were held. The Executive Committee* actively oversees the business of VIVA. The VIVA Board of Directors, comprising 10 Directors, serves pro-bono and ensures that VIVA's mission and vision are met.



Mrs Jennifer Yeo (Mdm Leong Lai Peng)
Founder and Chairman

Senior Consultant, RHTLaw
Advocate & Solicitor, Singapore
Solicitor, England & Wales

Appointed on 6 Feb 2006



Mdm Kuok Oon Kwong
Vice-Chair

Chairman, National Healthcare Group
Director, Shangri-La Hotel Ltd Singapore

Appointed on 9 Nov 2007



Mr Christopher Wilson

Co-Founder, Water and Healthcare
Foundation

Appointed on 15 Jan 2015



Ms Shulamite N K Khoo

Independent Director
CIMB Group

Appointed on 1 May 2018



Ms Cynthia Phua

Management Consultant
Former Singapore Member of
Parliament (2001-2011)

Appointed on 17 Jun 2020



Ms Tan Bee Lan

President,
Columbia China

Appointed on 1 Aug 2014



Ms Diaan-Yi Lin

Senior Partner,
McKinsey Singapore

Appointed on 7 Apr 2020



Mr Martino Tan

Managing Editor,
Mothership.sg

Appointed on 1 May 2018



Mdm Yeong Yoon Ying

Director (Special Duties),
Ministry of Communications and
Information

Appointed on 18 Jan 2020



Mr K.K Chua

Chairman of KDC
Director of Hayco

Appointed on 16 July 2021



Mr Tham Sai Choy

Chartered Accountant

Appointed on 01 January 2021

EXTERNAL ADVISORY BOARD

VIVA's External Advisory Board (EAB) is made up of an international panel of renowned doctors from the global field of cancer care and research. The VIVA Board of Directors seeks strategic advice and views from the EAB with regard to programmes and projects.

The EAB meets in Singapore once a year. At other times of the year, the Board would also call on the EAB for their expert views and thoughts when necessary.



Prof Ching-Hon Pui
Chairman

American Cancer Society Professor
Chair, Department of Oncology
Co-Leader, Hematological Malignancies
Program
Fahad Nassar Al-Rashid Chair of
Leukemia Research
Director, China Region,
St. Jude Global, St. Jude Children's
Research Hospital
Memphis, Tennessee, USA

Appointed on 19 Dec 2006



Prof Rupert Handgretinger
Member

Professor and Chairman, Department of
General Paediatrics and Hematology /
Oncology
Children's University Hospital
Tuebingen, GERMANY

Appointed on 7 Dec 2006



Prof Anjo Veerman
Member

Professor Emeritus, Paediatrics
Vrije Universiteit University Medical
Center
Amsterdam, THE NETHERLANDS

Appointed on 18 Dec 2006



Prof Leung Wing Hang
Member

Clinical Professor, Department of
Paediatrics and Adolescent Medicine
LKS Faculty of Medicine, The University of
Hong Kong

Appointed on 25 Feb 2020



Prof Melissa Hudson
Member

Member, St. Jude Faculty
Director, Cancer Survivorship Division
Co-Leader, Cancer Control &
Survivorship Program
The Charles E. Williams Endowed Chair
of Oncology-Cancer Survivorship
St. Jude's Children Research Hospital
USA

Appointed on 1 Mar 2022



Prof Godfrey Chan Chi-Fung
Member

Chief of Service, Department of
Paediatrics, HKU-Shenzhen Hospital
Tsao Yen-Chow Endowed Professor in
Paediatrics, HKU
Honorary Consultant, Department of
Paediatrics,
Hong Kong Children's Hospital
Hong Kong

Appointed on 1 Mar 2022



Prof Edward Holmes
Emeritus Member

President and CEO, Sanford Consortium
for Regenerative Medicine
Senior Fellow, A*STAR Advisor
National Research Foundation
SINGAPORE

Appointed on 30 Nov 2006

VIVA would like to express our warmest gratitude to all our donors, volunteers and supporters who contributed to our mission in 2022.

Help us rewrite the future of kids with cancer.



Scan the QR Code with your preferred banking app to donate instantly!

Connect with us



Phone call
+65 6221 2221



Website
viva.sg



VIVA Foundation for
Children with Cancer



Email Address
viva@viva.sg



Office Address
8 Sinaran Drive, #03-01 VIVA Hub,
Novena Specialist Centre,
Singapore 307470



Social Media
[@VivaFoundation](https://www.instagram.com/VivaFoundation)



VIVA Foundation for
Children with Cancer